A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

摘要: Abstract Objectives The aim of this study was to identify patients with esophageal cancer who may benefit from induction chemotherapy (IC) before neoadjuvant chemoradiotherapy (nCRT) on the basis a prognostic scoring model. Methods Between 1998 and 2015, 535 underwent nCRT were included for analysis, including 218 received IC (IC group) 317 did not receive (non-IC group). A model developed predict disease-free survival (DFS) Cox proportional hazards Results median follow-up time 63.5 months (range 8.0–178.5) survivors. 5-year DFS rates similar between non-IC groups (53.7% vs. 45.1%, p  = 0.196). Multivariate analysis determined that histologic grade, tumor location, baseline positron emission tomography maximum standard uptake value, lymph node size independent factors DFS. system constructed by using these four factors, total score ranging 0 6.2. When value used as cutoff, low-risk (≤3.5) high-risk (>3.5) identified. In group, had nonsignificantly higher pathologic complete response rate (  = 0.272) significantly better 0.03) than IC. After propensity matching, group demonstrated improved IC, observed in group. Conclusions On model, addition provide risk 3.5. Prospective validation is warranted.